These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31949575)

  • 1. Let-7f and miRNA-126 correlate with reduced cardiotoxicity risk in triple-negative breast cancer patients who underwent neoadjuvant chemotherapy.
    Zhu Z; Li X; Dong H; Ke S; Zheng WH
    Int J Clin Exp Pathol; 2018; 11(10):4987-4995. PubMed ID: 31949575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of circulating pro-angiogenic miRNAs with cardiotoxicity induced by epirubicin/cyclophosphamide followed by docetaxel in patients with breast cancer.
    Qin X; Chang F; Wang Z; Jiang W
    Cancer Biomark; 2018; 23(4):473-484. PubMed ID: 30452398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-130a Increases and Predicts Cardiotoxicity during Adjuvant Chemotherapy in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer.
    Feng Q; Ren Y; Hou A; Guo J; Mao Z; Liu S; Wang B; Bai Z; Hou X
    J Breast Cancer; 2021 Apr; 24(2):153-163. PubMed ID: 33818020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential of circulating pro-angiogenic microRNA expressions as biomarkers for rapid angiographic stenotic progression and restenosis risks in coronary artery disease patients underwent percutaneous coronary intervention.
    Dai R; Liu Y; Zhou Y; Xiong X; Zhou W; Li W; Zhou W; Chen M
    J Clin Lab Anal; 2020 Jan; 34(1):e23013. PubMed ID: 31495986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. microRNAs associated to anthracycline-induced cardiotoxicity in women with breast cancer: A systematic review and pathway analysis.
    Pereira JD; Tosatti JAG; Simões R; Luizon MR; Gomes KB; Alves MT
    Biomed Pharmacother; 2020 Nov; 131():110709. PubMed ID: 32937248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy.
    Li H; Hu B; Guo Z; Jiang X; Su X; Zhang X
    Yonsei Med J; 2019 Jan; 60(1):30-37. PubMed ID: 30554488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of HER2 codon 655 polymorphism with cardiotoxicity risk in Chinese HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab adjuvant chemotherapy.
    Tan L; Su X; Li X; Li H; Hu B
    Int J Clin Exp Pathol; 2020; 13(2):286-294. PubMed ID: 32211111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decrease of let-7f in low-dose metronomic Paclitaxel chemotherapy contributed to upregulation of thrombospondin-1 in breast cancer.
    Tao WY; Liang XS; Liu Y; Wang CY; Pang D
    Int J Biol Sci; 2015; 11(1):48-58. PubMed ID: 25552929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential of Circulating Proangiogenic MicroRNAs for Predicting Major Adverse Cardiac and Cerebrovascular Events in Unprotected Left Main Coronary Artery Disease Patients Who Underwent Coronary Artery Bypass Grafting.
    Shen J; Chang C; Ma J; Feng Q
    Cardiology; 2021; 146(3):400-408. PubMed ID: 33730720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients.
    Rigaud VO; Ferreira LR; Ayub-Ferreira SM; Ávila MS; Brandão SM; Cruz FD; Santos MH; Cruz CB; Alves MS; Issa VS; Guimarães GV; Cunha-Neto E; Bocchi EA
    Oncotarget; 2017 Jan; 8(4):6994-7002. PubMed ID: 28052002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robust expression of tumor suppressor miRNA's let-7 and miR-195 detected in plasma of Saudi female breast cancer patients.
    Qattan A; Intabli H; Alkhayal W; Eltabache C; Tweigieri T; Amer SB
    BMC Cancer; 2017 Nov; 17(1):799. PubMed ID: 29183284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating let-7f-5p improve risk prediction of prostate cancer in patients with benign prostatic hyperplasia.
    Ge Y; Wang Q; Shao W; Zhao Y; Shi Q; Yuan Q; Cui L
    J Cancer; 2020; 11(15):4542-4549. PubMed ID: 32489471
    [No Abstract]   [Full Text] [Related]  

  • 13. GDF-15 is a potential candidate biomarker for an elevated risk of cardiotoxicity in breast cancer patients receiving neoadjuvant dual anti-HER2 therapy.
    Tian C; Zhang H; Liu J; Xu M; Ma L
    Front Pharmacol; 2024; 15():1396133. PubMed ID: 38828460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between early-onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple-negative breast cancer patients and some novel autophagy-related polymorphisms in their genomic DNA: a real-world study.
    Liu B; An T; Li M; Yi Z; Li C; Sun X; Guan X; Li L; Wang Y; Zhang Y; Xu B; Ma F; Zeng Y
    Cancer Commun (Lond); 2018 Dec; 38(1):71. PubMed ID: 30514381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival.
    Silva J; García V; Zaballos Á; Provencio M; Lombardía L; Almonacid L; García JM; Domínguez G; Peña C; Diaz R; Herrera M; Varela A; Bonilla F
    Eur Respir J; 2011 Mar; 37(3):617-23. PubMed ID: 20595154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Association between expression of plasma miRNA and the risk of childhood acute lymphocytic leukemia].
    Yuan DM; Wu SY; Huang SL; Jiang WC; Ke YB
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Sep; 38(9):1252-1258. PubMed ID: 28910942
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients.
    Frères P; Bouznad N; Servais L; Josse C; Wenric S; Poncin A; Thiry J; Moonen M; Oury C; Lancellotti P; Bours V; Jerusalem G
    BMC Cancer; 2018 Jan; 18(1):102. PubMed ID: 29378531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
    Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
    Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].
    Liu L; Li XR; Hu YH; Zhang J
    Zhonghua Yi Xue Za Zhi; 2016 Mar; 96(12):940-3. PubMed ID: 27045718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.